drugset / Trial / NCT02173639
Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female Subjects
RandomizedCrossoverOpen-labelTreatment
Summary
The objective was to assess the relative bioavailability of a pilot scale linagliptin 2.5 mg / metformin 1000 mg fixed dose combination (FDC) tablet in comparison with single tablets of linagliptin 2.5 mg and metformin 1000 mg administered together.
Timeline
- Start
- 2009-04
- Primary completion
- 2009-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linagliptin | Unknown | 2.5 mg | — |
| Subject | Metformin | Small molecule | 1000 mg | — |
Indications
No indication recorded.